1. Old epilepsy drug repurposed as a low-cost metabolic vaccine booster increases T-cell responses 10-fold in a human trial Summary: A multiomic screen matched T-cell memory transcriptional signatures against more than 30,000 drug perturbation profiles, identifying lysine deacetylase inhibitors (KDACi) as candidate immunometabolic adjuvants. Low-dose sodium valproate enhanced glutaminolysis-dependent memory precursor (IL7Rhi PD1lo) differentiation in primary human CD8+ T cells and boosted memory responses across four murine infection/immunization models. In a randomized experimental human study (MEMRI, n=69 HLA-A*02:01+ adults) receiving seasonal trivalent influenza vaccine, a 7-day course of oral valproate produced a more than 10-fold increase in influenza-specific CD8+ T-cell counts and more than 2-fold increases in vaccine-strain IgG/IgA titres compared with controls, with expanded cross-strain antibody breadth and no increase in adverse events. Comment: For a clinician, this is a challenging manuscript to interpret, and the conclusions require careful consideration. This is an “old drug repurposing” story supported by in vitro, animal, and...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
